{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:52:49Z","timestamp":1793195569598,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>This study aimed to evaluate whether the Homocysteine (Hcy) level was elevated in chronic obstructive pulmonary disease (COPD) patients and its correlation with the occurrence and acute progression of COPD.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>From November 2014 to November 2015, COPD patients were enrolled from Beijing Chao-yang Hospital, and the the biological and clinical data were collected. These patients were tested in the non-acute exacerbation period and the acute exacerbation period, so they were defined as AECOPD group and Non-AECOPD group. Besides, 50 healthy subjects were recruited and defined as control group. Total plasma Hcy levels (antibodies-online, USA) were determined by enzyme-linked immunosorbent assay. Correlation analysis was used to analyze the correlation between serum Hcy level and ventilatory function. Using ROC curve, the diagnostic value of Hcy for the occurrence and acute progression of COPD was explored.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In this study, we found that Hcy levels in the Non-AECOPD group or the AECOPD group were significantly higher than those in the control group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Meanwhile, compared with the Non-AECOPD group, the Hcy level in the AECOPD group was significantly higher (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). In addition, according to the classification of GOLD grade, there was significant difference in the Hcy level among different GOLD grade groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The correlation analysis showed that in the AECOPD group and the Non-AECOPD group, Hcy levels presented a negative correlation with FEV1(<jats:italic>r<\/jats:italic>\u2009&lt;\u20090). Meanwhile, FEV1% was also negatively correlated with Hcy level (<jats:italic>r<\/jats:italic>\u2009&lt;\u20090). ROC curve analysis showed that when the cutoff value was set to 10.8\u2009\u03bcg\/ml, the specificity, sensitivity and AUC were the best, which were 0.980, 0.800, and 0.945, respectively. Besides, our results showed that when the cutoff value was set to 14.0\u2009\u03bcg \/ ml, the specificity, sensitivity and AUC were the best, which were 0.846, 0.680, and 0.802, respectively. In addition, compared with the prediction of acute progression of COPD, when Hcy level predicted the occurrence of COPD, its specificity (0.980 vs. 0.846, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and sensitivity (0.800 vs. 0.680, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) were significantly higher.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Hcy level is positively correlated with the severity of COPD patients, which has predictive value for the occurrence of COPD and acute progression.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12890-020-01265-w","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T11:02:37Z","timestamp":1599476557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The diagnostic value of homocysteine for the occurrence and acute progression of chronic obstructive pulmonary disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Bing","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"issue":"9","key":"1265_CR1","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1177\/0300060518781642","volume":"46","author":"B Wei","year":"2018","unstructured":"Wei B, Sheng Li C. Changes in Th1\/Th2-producing cytokines during acute exacerbation chronic obstructive pulmonary disease. J Int Med Res. 2018;46(9):3890\u2013902.","journal-title":"J Int Med Res"},{"issue":"4","key":"1265_CR2","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0021-9258(17)35979-3","volume":"261","author":"JD Finkelstein","year":"1986","unstructured":"Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Adaptation to methionine excess. J Biol Chem. 1986;261(4):1582\u20137.","journal-title":"J Biol Chem"},{"issue":"11","key":"1265_CR3","first-page":"OC17","volume":"10","author":"NA Khan","year":"2016","unstructured":"Khan NA, Saini H, Mawari G, Kumar S, Hira HS, Daga MK. The effect of folic acid supplementation on Hyperhomocysteinemia and pulmonary function parameters in chronic obstructive pulmonary disease: a pilot study. J Clin Diagn Res. 2016;10(11):OC17\u201321.","journal-title":"J Clin Diagn Res"},{"issue":"9","key":"1265_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.numecd.2008.12.006","volume":"19","author":"FL Fimognari","year":"2009","unstructured":"Fimognari FL, Loffredo L, Di Simone S, Sampietro F, Pastorelli R, Monaldo M, Violi F, D'Angelo A. Hyperhomocysteinaemia and poor vitamin B status in chronic obstructive pulmonary disease. Nutr Metab Cardiovasc Dis. 2009;19(9):654\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1265_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1475-2891-14-6","volume":"14","author":"P Ganguly","year":"2015","unstructured":"Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6.","journal-title":"Nutr J"},{"issue":"5","key":"1265_CR6","first-page":"3913","volume":"18","author":"J Yu","year":"2019","unstructured":"Yu J, Zhang LL, Wu XP, Zhao R, Meng ZX, Wang K, Wang B, Wang H, Shi ZL, Li GX. Homocysteine inhibits the viability and migration ability of human umbilical vein endothelial cells by downregulating the expression of vascular endothelial growth factor. Exp Ther Med. 2019;18(5):3913\u20139.","journal-title":"Exp Ther Med"},{"key":"1265_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fpubh.2019.00069","volume":"7","author":"D Chaudhary","year":"2019","unstructured":"Chaudhary D, Sharma N, Senapati S. Serum Homocysteine could be used as a predictive marker for chronic obstructive pulmonary disease: a meta-analysis. Front Public Health. 2019;7:69.","journal-title":"Front Public Health"},{"key":"1265_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3389\/fphar.2017.00624","volume":"8","author":"Y He","year":"2017","unstructured":"He Y, Liu S, Zhang Z, Liao C, Lin F, Yao W, Chen Y. Imbalance of endogenous hydrogen sulfide and Homocysteine in chronic obstructive pulmonary disease combined with cardiovascular disease. Front Pharmacol. 2017;8:624.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1265_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/COPD.S2147","volume":"2","author":"TA Seemungal","year":"2007","unstructured":"Seemungal TA, Lun JC, Davis G, Neblett C, Chinyepi N, Dookhan C, Drakes S, Mandeville E, Nana F, Setlhake S, et al. Plasma homocysteine is elevated in COPD patients and is related to COPD severity. Int J Chron Obstruct Pulmon Dis. 2007;2(3):313\u201321.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1265_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648\u201354.","journal-title":"Eur Respir J"},{"issue":"4","key":"1265_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","volume":"187","author":"J Vestbo","year":"2013","unstructured":"Vestbo J, Hurd SS, Agust\u00ed AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347\u201365.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"1265_CR12","first-page":"1711","volume":"15","author":"P Hu","year":"2017","unstructured":"Hu P, Wang J, Zhang Y. Analysis of homocysteine and blood lipid levels in patients with chronic obstructive pulmonary disease. Chinese J General Practice. 2017;15(10):1711\u20133.","journal-title":"Chinese J General Practice"},{"issue":"1","key":"1265_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1183\/09031936.00066212","volume":"42","author":"K Nunomiya","year":"2013","unstructured":"Nunomiya K, Shibata Y, Abe S, Inoue S, Igarashi A, Yamauchi K, Aida Y, Kishi H, Sato M, Watanabe T, et al. Hyperhomocysteinaemia predicts the decline in pulmonary function in healthy male smokers. Eur Respir J. 2013;42(1):18\u201327.","journal-title":"Eur Respir J"},{"issue":"4","key":"1265_CR14","first-page":"392","volume":"40","author":"H Fu","year":"2019","unstructured":"Fu H, Xiao L, Peng Y, Wei Q, Feng J. The diagnostic value of high-sensitivity troponin I, homocysteine, and inflammatory markers in acute exacerbation of chronic obstructive pulmonary disease. Int J Laboratory Med. 2019;40(4):392\u20138.","journal-title":"Int J Laboratory Med"},{"issue":"4","key":"1265_CR15","first-page":"653","volume":"39","author":"C Feng","year":"2018","unstructured":"Feng C, Yao X, Wang H, Wang F, Ying Q. The diagnostic value of serum C-reactive protein (CRP) combined with homocysteine (Hcy) detection for acute exacerbation of chronic obstructive pulmonary disease. Jilin Med J. 2018;39(4):653\u20134.","journal-title":"Jilin Med J"},{"issue":"3","key":"1265_CR16","first-page":"323","volume":"30","author":"P Li","year":"2017","unstructured":"Li P. The clinical value of the detection of Homocysteine in the diagnosis of chronic obstructive pulmonary disease. J Med Theory Practice. 2017;30(3):323\u20134.","journal-title":"J Med Theory Practice"},{"issue":"11","key":"1265_CR17","first-page":"OC17","volume":"10","author":"NA Khan","year":"2016","unstructured":"Khan NA, Saini H, Mawari G, Kumar S, Hira HS, Daga MK. The effect of folic acid supplementation on hyperhomocysteinemia and pulmonary function parameters in chronic obstructive pulmonary disease. J Clin Diagn Res. 2016;10(11):OC17\u201321.","journal-title":"J Clin Diagn Res"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01265-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-020-01265-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01265-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T23:14:34Z","timestamp":1630970074000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-01265-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-01265-w","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"30 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of Beijing Chao-Yang Hospital, Capital Medical University. Written informed consent was obtained from all the study subjects before enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}